Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598998 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
A Phase 1 study of Anaplastic Large Cell Lymphoma and Recurrent Follicular Lymphoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 3
- Study locations
NCT03598998 is a Phase 1 study of Anaplastic Large Cell Lymphoma and Recurrent Follicular Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 13 participants, below the 60-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03598998, a Phase 1 study of Anaplastic Large Cell Lymphoma and Recurrent Follicular Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Pralatrexate
Study Locations (3)
California
- City of Hope Medical Center - Duarte
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2026-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03598998
The ClinicalTrials.gov registry entry for NCT03598998 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (78% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Anaplastic Large Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03598998 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03598998 about?
NCT03598998 is a clinical study titled "Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas". This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop t...
What is the current status of trial NCT03598998?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-02-04. Estimated completion is 2026-02-26.
What conditions does trial NCT03598998 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma.
What interventions are being tested in trial NCT03598998?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Pralatrexate (DRUG).
Who is sponsoring clinical trial NCT03598998?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03598998 being conducted?
This trial has 3 study locations across California, Georgia, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
RECRUITING · Phase 1
-
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Anaplastic Large Cell Lymphoma
All registered trials for this condition
Recurrent Follicular Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.